Q3 EPS Estimates for Sanara MedTech Raised by HC Wainwright

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimate for Sanara MedTech from ($0.32) to ($0.24), maintaining a "Buy" rating with a target price of $54.00.
• Sanara MedTech's latest earnings report showed a loss of ($0.23) per share, which was better than the consensus estimate of ($0.33), suggesting a positive trend in performance.
• The company has attracted interest from institutional investors, with JPMorgan Chase increasing its holdings by 234.5% in the last quarter.

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Equities research analysts at HC Wainwright boosted their Q3 2025 EPS estimates for shares of Sanara MedTech in a research report issued to clients and investors on Monday, August 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.24) per share for the quarter, up from their prior estimate of ($0.32). HC Wainwright has a "Buy" rating and a $54.00 price target on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech's Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.08) EPS and FY2026 earnings at ($0.84) EPS.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.10. The firm had revenue of $25.83 million during the quarter, compared to analyst estimates of $25.15 million. Sanara MedTech had a negative net margin of 10.22% and a negative return on equity of 26.43%.

Sanara MedTech Price Performance

Shares of SMTI traded down $0.70 during mid-day trading on Wednesday, reaching $33.25. 9,070 shares of the stock traded hands, compared to its average volume of 34,261. The firm has a fifty day moving average price of $27.92 and a 200 day moving average price of $30.26. The company has a market cap of $295.93 million, a price-to-earnings ratio of -28.61 and a beta of 1.26. The company has a current ratio of 2.26, a quick ratio of 2.03 and a debt-to-equity ratio of 1.25. Sanara MedTech has a 1 year low of $23.53 and a 1 year high of $39.08.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Marshall Wace LLP grew its position in Sanara MedTech by 144.3% in the second quarter. Marshall Wace LLP now owns 71,511 shares of the company's stock worth $2,030,000 after acquiring an additional 42,237 shares in the last quarter. Renaissance Technologies LLC grew its position in Sanara MedTech by 152.9% in the fourth quarter. Renaissance Technologies LLC now owns 35,400 shares of the company's stock worth $1,175,000 after acquiring an additional 21,400 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Sanara MedTech in the second quarter worth $382,000. Nuveen LLC purchased a new position in Sanara MedTech in the first quarter worth $326,000. Finally, JPMorgan Chase & Co. grew its position in Sanara MedTech by 234.5% in the fourth quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company's stock worth $451,000 after acquiring an additional 9,516 shares in the last quarter. 8.10% of the stock is currently owned by hedge funds and other institutional investors.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.